leisure time -WSS

leisure time

author：comprehensive 2025-10-02 19:20:50 - browse：53

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： How to fix the rural physician shortage in the U.S.

hotspot

WSS

Study finds new variant for Parkinson’s in African populations

Congress gives doctors Medicare pay bump

Appeals court upholds limits to abortion pill

Pfizer highlights cancer drugs it thinks could reignite investor interest

FDA panel gives mixed vote on blood pressure devices

How Long Island became the ‘eugenics capital of the world’

focus

leisure time

leisure time

How one medical school became remarkably diverse

RSV vaccines may be linked to small increased risk of developing GBS

United colonoscopy coverage change 'may cost lives,' doctors say

Psilocybin's anti

Continuity nursing helped my family in our darkest PICU moments

Feds fine Medicare Advantage plans for overcharging members

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

CDC advisory panel says seniors 'may' get RSV vaccine

As demand for Covid shots wanes, Moderna seeks its next success

Drug firms test therapies to halt Alzheimer’s before symptoms arise

leisure time

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

How to fix the rural physician shortage in the U.S.

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

House looks to weaken Medicare negotiation

hotspot

entertainment

focus

Wikipedia